Currently, the world is facing the pandemic of a novel strain of beta‐coronavirus known as
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Acute respiratory distress …

Abstract Severe COVID-19 (coronavirus disease 2019) is associated with elevated
inflammatory markers, consistent with cytokine release syndrome (CRS). Tocilizumab is an …

The novel coronavirus disease 2019 (COVID-19) worldwide pandemic has placed a
significant burden on hospitals and healthcare providers. The immune response to this …

Background: Several studies have revealed the potential use of tocilizumab in treating
COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab …

Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin‐6 receptor,
holds the potential for treating coronavirus disease 2019 (COVID‐19) patients, particularly …

Abstract Coronavirus disease 2019 (COVID‐19) can lead to a massive cytokine release. The
use of the anti‐interleukin‐6 receptor monoclonal antibody tocilizumab (TCZ) has been …

Objectives Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …

Limited evidence is available to guide treatment of coronavirus disease 2019 (COVID-19),
caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A …

Introduction As the pandemic progresses, the pathophysiology of COVID-19 is becoming
more apparent, and the potential for tocilizumab is increasing. However, the clinical efficacy …

The severe acute respiratory syndrome coronavirus‑2 (SARS‑CoV‑2) pandemic is a
significant global issue that has major implications for the healthcare system. The mortality …